펩트론

087010KOSDAQ

51.5 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment17.0 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Peptron develops smart pharmaceuticals using peptide engineering and sustained-release technology, operating a GMP large-scale production facility for clinical trials and commercial products. The pharmaceutical industry is characterized by high R&D costs and long-term profitability, with the sustained-release drug sector maintaining an oligopolistic structure due to high manufacturing barriers even after patent expirations.

Number of Employees

160people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-9.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

21.10Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼16.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -22.9% (improving, 3yr)

Detailed News Sentiment

20 totalPositive 10Neutral 8Negative 2Average Sentiment Score 68

Positive
기술특례 300社 시대…코스닥 IPO 시총 62% 차지
펩트론을 포함한 첨단기술 특례 상장 기업 증가로 코스닥 시장의 성장과 혁신 기업 유치가 가속화되고 있다.
Positive
"글로벌 사업화 대비"…펩트론, 제2공장 시공계약
펩트론의 제2공장 건설 계약 체결로 장기지속형 의약품 생산 능력 강화 및 글로벌 시장 진출 기대감 증가.
Neutral
[임상 업데이트] 올릭스, 탈모치료제 ‘OLX104C’ 연내 2a상 첫...
임상 업데이트는 관련 제약바이오 분야에 영향을 미치나 펩트론의 직접적인 영향은 제한적이다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 160,200Won52-week high 386,00052-week low 103,600

1-month return1.0Point

1m -11.88% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral[기재정정]신규시설투자등2026-09-03
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (PT403의 제1상 임상시험계획 승인 신청)2026-08-25
Neutral반기보고서 (2026.06)2026-08-14